Liposomal Doxorubicin, but Not Platinum-Taxane, Supports MHC-II Expression and Immune Maturation in the Ovarian Tumor Microenvironment
Altogether, the results support the notion that PLD has a greater capacity for immunopotentiation, which may be important to consider if immunotherapy approaches are adapted for ovarian tumors in the future.
Authors
- Xiao Lei Chen (ORCID: https://orcid.org/0000-0001-7998-9963)
- Breana Hill (ORCID: https://orcid.org/0000-0003-2240-4009)
- Antonia Boyer
- Dwayne G. Stupack (ORCID: https://orcid.org/0000-0003-4396-5745)
- Safir Ullah Khan (ORCID: https://orcid.org/0000-0002-7962-0506)
- James Lee (ORCID: https://orcid.org/0000-0003-3079-5484)
- Duygu Ozmadenci (ORCID: https://orcid.org/0000-0002-5463-7766)
- David D. Schlaepfer (ORCID: https://orcid.org/0000-0003-4814-9210)
- Elise Tahon
- Terrance J. Haanan
Institutions
- University of California San Diego (US)
- Université Laval (CA)
- New York University (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3390/cancers17172827
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.80